WO2003025130A3 - Receptors and membrane-associated proteins - Google Patents

Receptors and membrane-associated proteins Download PDF

Info

Publication number
WO2003025130A3
WO2003025130A3 PCT/US2002/029220 US0229220W WO03025130A3 WO 2003025130 A3 WO2003025130 A3 WO 2003025130A3 US 0229220 W US0229220 W US 0229220W WO 03025130 A3 WO03025130 A3 WO 03025130A3
Authority
WO
WIPO (PCT)
Prior art keywords
membrane
remap
associated proteins
receptors
polynucleotides
Prior art date
Application number
PCT/US2002/029220
Other languages
French (fr)
Other versions
WO2003025130A2 (en
Inventor
Bridget A Warren
Kimberly J Gietzen
Preeti G Lal
Yuming Xu
Uyen K Tran
Sally Lee
Mark L Borowsky
Shanya D Becha
Madhusudan M Sanjanwala
Kavitha Thangavelu
Original Assignee
Incyte Genomics Inc
Bridget A Warren
Kimberly J Gietzen
Preeti G Lal
Yuming Xu
Uyen K Tran
Sally Lee
Mark L Borowsky
Shanya D Becha
Madhusudan M Sanjanwala
Kavitha Thangavelu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Bridget A Warren, Kimberly J Gietzen, Preeti G Lal, Yuming Xu, Uyen K Tran, Sally Lee, Mark L Borowsky, Shanya D Becha, Madhusudan M Sanjanwala, Kavitha Thangavelu filed Critical Incyte Genomics Inc
Priority to AU2002326910A priority Critical patent/AU2002326910A1/en
Priority to CA002459137A priority patent/CA2459137A1/en
Publication of WO2003025130A2 publication Critical patent/WO2003025130A2/en
Publication of WO2003025130A3 publication Critical patent/WO2003025130A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Various embodiments of the invention provide human receptors and membrane-associated proteins (REMAP) and polynucleotides which identify and encode REMAP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of REMAP.
PCT/US2002/029220 2001-09-14 2002-09-12 Receptors and membrane-associated proteins WO2003025130A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002326910A AU2002326910A1 (en) 2001-09-14 2002-09-12 Receptors and membrane-associated proteins
CA002459137A CA2459137A1 (en) 2001-09-14 2002-09-12 Receptors and membrane-associated proteins

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US32215701P 2001-09-14 2001-09-14
US60/322,157 2001-09-14
US32602901P 2001-09-28 2001-09-28
US60/326,029 2001-09-28
US32738001P 2001-10-05 2001-10-05
US60/327,380 2001-10-05
US32919801P 2001-10-12 2001-10-12
US60/329,198 2001-10-12
US34374201P 2001-10-19 2001-10-19
US60/343,742 2001-10-19
US34398001P 2001-11-02 2001-11-02
US34390601P 2001-11-02 2001-11-02
US60/343,980 2001-11-02
US60/343,906 2001-11-02
US33242601P 2001-11-16 2001-11-16
US60/332,426 2001-11-16
US36433802P 2002-03-13 2002-03-13
US60/364,338 2002-03-13
US36449402P 2002-03-15 2002-03-15
US60/364,494 2002-03-15
US36924802P 2002-03-29 2002-03-29
US60/369,248 2002-03-29

Publications (2)

Publication Number Publication Date
WO2003025130A2 WO2003025130A2 (en) 2003-03-27
WO2003025130A3 true WO2003025130A3 (en) 2003-10-23

Family

ID=27582771

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/029220 WO2003025130A2 (en) 2001-09-14 2002-09-12 Receptors and membrane-associated proteins

Country Status (3)

Country Link
AU (1) AU2002326910A1 (en)
CA (1) CA2459137A1 (en)
WO (1) WO2003025130A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033727A1 (en) 2001-10-12 2003-04-24 Yamanouchi Pharmaceutical Co., Ltd. Method of screening cell death inhibitor
CA2517953A1 (en) * 2003-03-04 2004-09-16 Astellas Pharma Inc. Novel gene relating to fibrotic conditions
WO2005005615A2 (en) 2003-07-08 2005-01-20 Fox Chase Cancer Center Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer
EP2031063B1 (en) 2004-06-18 2013-11-06 Duke University Modulators of odorant receptors
WO2009026660A1 (en) 2007-08-30 2009-03-05 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
PT2190469E (en) * 2007-09-04 2015-06-25 Compugen Ltd Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
AU2013204933B2 (en) * 2007-09-04 2016-02-04 Compugen Ltd. Polypeptides and polynucleotides related to ai216611, and uses thereof as a drug target for producing drugs and biologics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480968A (en) * 1989-12-01 1996-01-02 The United States Of America As Represented By The Department Of Health And Human Services Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480968A (en) * 1989-12-01 1996-01-02 The United States Of America As Represented By The Department Of Health And Human Services Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HELLYER ET AL.: "Cloning of the rat ErbB3 cDNA and characterization of the recombinant protein", GENE, vol. 165, 1995, pages 279 - 284, XP004043156 *
PLOWMAN ET AL.: "Molecular cloning and expression of an additional epidermal growth factor receptor-related gene", PROC. NATL. ACAD. SCI. USA, vol. 87, July 1990 (1990-07-01), pages 4905 - 4909, XP002967259 *

Also Published As

Publication number Publication date
AU2002326910A1 (en) 2003-04-01
CA2459137A1 (en) 2003-03-27
WO2003025130A2 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
WO2001098351A3 (en) G-protein coupled receptors
WO2001042288A3 (en) G-protein coupled receptors
WO2003027228A3 (en) Receptors and membrane-associated proteins
WO2001057085A3 (en) G-protein coupled receptors
WO2003048305A3 (en) Receptors and membrane-associated proteins
WO2001087937A3 (en) G-protein coupled receptors
WO2001098323A3 (en) G-protein coupled receptors
WO2001098354A3 (en) Human receptors
WO2003029437A3 (en) Secreted proteins
WO2002072794A3 (en) Immunoglobulin superfamily proteins
WO2003070902A3 (en) Receptors and membrane-associated proteins
WO2002094990A3 (en) Receptors and membrane-associated proteins
WO2003004615A3 (en) Secreted proteins
WO2001072836A3 (en) G-protein coupled receptors
WO2002026825A3 (en) G-protein coupled receptors
WO2001090359A3 (en) G-protein coupled receptors
WO2003068943A3 (en) Secreted proteins
WO2003025130A3 (en) Receptors and membrane-associated proteins
WO2004100774A3 (en) Receptors and membrane-associated proteins
WO2001066742A3 (en) G-protein coupled receptors
WO2000065054A3 (en) Human membrane-associated proteins
WO2002063004A3 (en) G-protein coupled receptors
WO2002057454A3 (en) Receptors and membrane-associated proteins
WO2002066646A3 (en) Neurotransmission-associated proteins
WO2003087300A3 (en) Secreted proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE CH CY DE DK FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2459137

Country of ref document: CA

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP